A new study suggests amylin could be a second amyloid and a new biomarker for age related dementia and Alzheimer's disease.
Researchers report memantine, an FDA approved drug, may not only alleviate symptoms of mild Alzheimer's disease, but could also prevent progression of the disease if used before symptoms appear.
The protein beta-arrestin-2 increases tau tangle accumulation in Alzheimer's disease and frontotemporal dementia but interfering with the removal of excess tau from the brain.
Researchers have invented a probe that lights up when it binds to a misfolded amyloid peptide.
Researchers found a key difference in the brains of people with Alzheimer’s disease and those who are cognitively normal but still have brain plaques that characterize this type of dementia.
A new study reports a computer simulation has been able to explore the initial steps of the molecular processes that lead to Alzheimer's disease.
Researchers reveal a compound in green tea extract may help protect the brain against cognitive decline associated with Alzheimer's by coating toxic oligomers.
TNFR1 receptors arrange themselves into clusters, joining together trimers and making oligomers that create a pro-inflammatory response observed in a variety of diseases.
Raman spectroscopy techniques allows researchers to take a closer look at the elusive amyloid beta.
A new study reports a molecular chaperone can inhibit a key stage in the development of Alzheimer's disease.
A new study has pinpointed a catalytic trigger for the onset of Alzheimer's disease. The findings could play a central role in the diagnostics and new drug development for neurodegenerative diseases.
Researchers have discovered how synthetic molecules latch onto amyloid peptide fibrils. The discovery could help develop new therapies to halt Alzheimer's disease.
